Tyrosine aminotransferase (TAT; L-tyrosine:2-oxoglutarate aminotransferase, EC 2.6.1.5) gene activity is stimulated by glucocorticoids and glucagon and is repressed by insulin. Expression and responsiveness to the different signal transduction pathways are restricted to the liver, in which the gene is activated shortly after birth. Here we provide a model for the basis of this tissue specificity of the hormonal control. In the two enhancers mediating hormone induction of TAT gene activity we find the hormone response elements in combination with binding sites for constitutive liver-enriched transcription factors: proteins of the hepatocyte nuclear factor 3 family bind in the vicinity of the glucocorticoid response element located 2.5 kb upstream of the transcription start site, while hepatocyte nuclear factor 4 interacts with an essential element in the cAMP-responsive enhancer at -3.6 kb. By juxtaposing the liver-specific element and the target sequence of the signal transduction pathway the regulatory properties of either enhancer can be reconstituted. Thus, the interdependence of the respective enhancer motifs restricts the hormonal activation of the TAT gene to the liver. The coincidence of the onset ofTAT gene expression around birth with the perinatal changes in the concentrations of glucocorticoids, glucagon, and insulin suggests cooperation of signal transduction pathways and cell type-specific transcription factors in the developmental activation of the TAT gene.
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Gene activity is regulated in response to temporal, spatial, and environmental cues. In the last 10 years many sequence motifs have been discovered which are involved in determining tissue-specific and developmentally regulated gene expression. These cis-regulatory elements interact with trans-acting factors which influence the rate of transcription and which often exhibit correspondingly restricted expression patterns (1, 2) . Similarly, changes in gene expression in response to external signals such as growth factors and hormones are mediated by altering the function of specific transcription factors. Two major types of signal transduction pathways have been elucidated: (i) signaling molecules such as steroid hormones influence gene activity by inducing DNA binding of their intracellular receptors (3, 4) ; (ii) binding of many growth factors or peptide hormones to specific cellsurface receptors elicits a cascade of events mediated by second messengers, which affect the activity of protein kinases and phosphatases, as well as Ca2+ levels. These changes finally result in the modification of specific transcription factors, thereby changing their activities (5) .
While the components of the signal transduction pathways are mostly of ubiquitous nature, hormonal stimulation of a particular gene is often restricted to certain cell types. We have chosen the tyrosine aminotransferase (TAT) gene as a model system to study the basis of this cell type-specificity of The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
hormone induction and its role in developmental gene activation. The TAT gene is transcriptionally responsive to members of both classes of signaling pathways. It is induced by glucocorticoids and glucagon, acting via its intracellular mediator cAMP (6) (7) (8) , and is repressed by insulin (9) . The hormone-regulated expression is restricted to the parenchymal cells of the liver, in which the gene is activated shortly after birth (10, 11) . We show here that in the two enhancers at -2.5 and -3.6 kb (relative to the transcription start site) which respond to glucocorticoids and glucagon, respectively (12, 13) , the hormone response elements synergize with binding sites for the liver-enriched transcription factors hepatocyte nuclear factor 3 (HNF3; refs. 14 and 15) and HNF4 (16) . Therefore, the interdependence of the hormone response elements and cell type-specific enhancer motifs seems to be the basis of the strictly liver-specific hormonal inducibility ofTAT gene expression and may provide the switch for the developmentally timed activation of the gene.
EXPERIMENTAL PROCEDURES Plasmid Constructions. In plasmid 3.OTK the Sal I-Kpn I fragment from pTATCAT (12) was cloned into the polylinker of pBLCAT2 (17) , generating a construct containing TAT 5' flanking sequences from -2950 to -351 bp in front of the herpes simplex virus thymidine kinase (TK) promoter. Constructs -2.5HSTK and 2xGRETK are described elsewhere (18) . The constructs containing one or two copies of the TAT glucocorticoid response element (GRE) in front of the TAT promoter have been described previously as GRE-351TAT and 2GRE-351TAT (19) . In all other constructs depicted in Fig. 4A the following oligonucleotides were cloned in the sense orientation into the BamHI site of GRE-351TAT: HNF3(TAT-2.5), 5'-GATCTACGCAGGACTTGTTTGT-TCTAGTCG-3'; HNF3(TAT-11), 5'-GATCCGACGTTTC-TCAATATTTGCTCTGGCAGATA-3'; -llmut, 5'-GATC-CGACGTTTATACATATTTTATCTGGCAGATA-3 '; HNF4, 5'-GATCTGCTGCTCTTTGATCTG-3'; HNF4mut, 5'-GATCTGCTGCGAGGGGATCTG-3' (the mutated base pairs are underlined). The cAMP response element (CRE)-HNF4 and CRE-HNF4mut constructs (Fig. 4B) ITo whom reprint requests should be addressed.
Cell Culture and Transient Transfections. All experiments were performed with FTO2B hepatoma and XC fibrosarcoma ("fibroblast") rat cell lines. Cell culture, transfection experiments, and chloramphenicol acetyltransferase (CAT) assays were performed as described (13) . Cells were harvested 48 hr after electroporation and hormone additions.
Gel Mobility-Shift Assays. Mobility-shift experiments were performed as described (18) . Rat liver nuclear extract was prepared and partially purified by DEAE-Sepharose chromatography (21) . The antisera directed against HNF3a, -/3, and -y were generously provided by V. Prezioso and J. Darnell (15) . HNF4-specific antiserum was kindly provided by F. Sladek and J. Darnell (16) .
RESULTS
Members of the HNF3 Family of Liver-Enriched Transcription Factors Bind to the Glucocorticoid-Inducible Enhancer of the TAT Gene. The TAT gene is induced by glucocorticoids exclusively in the liver, and this cell-type specificity of the hormone response can be reproduced in transienttransfection experiments (Fig. 1 ). Constructs containing TAT 5' flanking sequences, including the glucocorticoid-inducible enhancer at -2.5 kb (12), in front of the promoter of the herpes simplex virus TK gene, are induced >50-fold in hepatoma cells by the addition ofthe synthetic glucocorticoid dexamethasone. Whereas two copies of the GRE from the TAT enhancer (2xGRETK) stimulate the TK promoter in both hepatoma and fibroblast cells, the complete enhancer either contained on a 250-bp fragment (-2.5HSTK) or in its natural position at -2.5 kb (3.OTK) strongly responds to hormone only in the hepatoma cell line. Thus, it appears that sequences located within the glucocorticoid-inducible enhancer restrict its activity to the liver.
We noted a sequence motif -60 bp downstream ofthe GRE with striking homology to an important element contained in the constitutive liver-specific TAT enhancer located at -11 kb ( Fig. 2D ; ref. 22) , which has recently been found to bind liver-enriched transcription factors ofthe HNF3 family (D.N. and G.S., unpublished work). To test whether the sequence in the glucocorticoid-inducible enhancer also interacts with HNF3 proteins, we performed gel mobility-shift analyses with an oligonucleotide containing the respective sequence motif (TAT-2.5; Fig. 2 ). With extracts prepared from either hepatoma or fibroblast cells several prominent protein-DNA complexes were observed, only one of which was common to both extracts ( Fig. 2A) . To define the specificity of the protein-DNA complexes we performed competition experiments with different oligonucleotides, which showed that the sequence derived from the TAT enhancer at -2.5 kb contained an HNF3 binding site ( whereas complex formation is not influenced by excess of an HNF4 binding site (Fig. 2B, lanes 1-4) . Consistent with these results, the TAT-2.5 oligonucleotide competed for formation of the complexes obtained with the HNF3 motif from the transthyretin gene (Fig. 2B, lanes 6 and 7) . Further, with the help of specific antisera (kindly provided by V. Prezioso and J. Darnell), we demonstrated that HNF3a, -/3, and -y were contained in the hepatoma cell-specific protein-DNA complexes obtained with the sequence from the TAT enhancer at -2.5 kb (Fig. 2C) .
Thus, an HNF3 binding site is located in the vicinity of the GRE in the glucocorticoid-inducible TAT enhancer and it A comparison of the sequence from the TAT enhancer at C , -3.6 kb and the published HNF4 consensus binding site (26) reveals homology in 7 of 12 positions (Fig. 3D) . The DNA contacts determined by methylation interference analysis (Fig. 4) . motif was mutated. Mutation of five nucleotides which abolished protein-DNA binding in vitro (Fig. 2B, lane 5) impaired the hormone-dependent stimulation of the TAT promoter, indicating that the HNF3 motif synergizes with the GRE. Thus, the regulatory properties of the TAT enhancer at -2.5 kb can be reconstituted by combining its GRE and HNF3 binding site. Likewise, the liver-specific and cAMPresponsive activity of the TAT enhancer at -3.6 kb can be reconstituted by juxtaposing the HNF4 motif and the CRE in front of the heterologous TK promoter (Fig. 4B) . Mutations in the HNF4 binding site which affect DNA binding (Fig. 3B , lane 3) reduce basal as well as cAMP-induced activities of the corresponding construct.
To see whether the synergism between the cell typespecific and the hormone response elements was specific to the combinations found in the two TAT enhancers, we constructed reporter plasmids in which the binding sites for the two liver-enriched factors were swapped. As documented in Fig. 4A , the HNF3 motif can be replaced by the HNF4 binding site from the TAT enhancer at -3.6 kb, and again mutation of the latter results in loss of synergism with the GRE in a promoter distal position. In contrast, neither HNF3 binding site tested in combination with the CRE was able to confer liver-specific and cAMP-responsive stimulation of the TK promoter (Fig. 4B) . Whereas the HNF3 motifs were functional in either orientation in combination with the GRE, both HNF3 motifs (TAT-11 and TAT-2.5) when linked to the CRE were inactive in either orientation (data not shown). These results may indicate a strict requirement for a specific alignment of the CRE and an adjacent binding site not met by our constructs.
DISCUSSION
The work presented above has documented that the liverenriched transcription activators HNF3a, -13, and -y and HNF4 specifically interact with two hormone-responsive enhancers of the TAT gene. While binding sites for these transcription factors have been characterized in constitutive regulatory sequences of other liver-specific genes (16, 23, (26) (27) (28) (29) (30) , our results demonstrate that these elements in hormone-responsive enhancers can function to restrict the activity of ubiquitous signal transduction pathways to the liver. In the TAT enhancer at -3.6 kb an HNF4 binding site synergizes with the CRE to confer cAMP-inducible hepatoma cell-specific stimulation. HNF3 proteins bind in the vicinity of the GRE in the glucocorticoid-inducible enhancer at -2.5 kb, at a sequence motif which was previously characterized as a second GRE (12, 31) . Since the methylation interference pattern of the HNF3 protein-DNA complexes correlates with the genomic footprint observed in hepatoma cells (31) , HNF3 proteins most likely interact in vivo. Which of the three HNF3 proteins cooperates in vivo, or whether they form a redundant system, has to remain an open question until gene knockout experiments have been performed. The regulatory properties of the enhancer can be reconstituted by juxtaposing the HNF3 binding site and the GRE. In vivo, it is likely that liver-enriched factors of the C/EBP family also participate in determining the strong glucocorticoid response in the liver (32, 33) . The recently postulated liver-enriched protein HNF5 (32, 33) is probably identical with HNF3, since the HNF3 binding site that we have identified coincides with one of the two putative HNF5 motifs described in the TAT enhancer at -2.5 kb and displays a methylation interference pattern identical with that published for HNF5. Moreover, the second postulated HNF5 binding site also interacts with HNF3 proteins (data not shown).
In some systems, including the tryptophan oxygenase gene and the mouse mammary tumor virus long terminal repeat, sequence elements for ubiquitous factors adjacent to a GRE have been documented to be important for hormonedependent stimulation (34) (35) (36) (37) (38) . Transfection experiments suggest that the presence of steroid hormone receptors is sufficient to allow a transcriptional response upon administration of the respective hormone (e.g., Fig. 4A ). We have shown here that a tissue-specific response can be elicited through ubiquitous signaling pathways by coupling the target 
M-GR-EB
sequence (hormone response element) to binding sites for cell type-specific transcription factors. The interdependence of two or more essential transcriptional control elements permits a finely tuned response also to small differences in factor or hormone concentrations (39) . Whereas a single GRE is functional in close proximity to the transcription start site, cooperation with a second GRE or another transcription factor binding site is required for activation from a promoterdistal position ( Fig. 4A; ref. 19 ). As shown in Fig. 4B and by the mutational analysis of the cAMP-responsive enhancer (13), a CRE alone is not capable of eliciting a cAMP response. Thus, the upstream location combined with the modular organization of the two hormone-inducible enhancers of the TAT gene determines the tissue-specificity of the response.
The results presented in this study ascribe an important role to HNF3 and HNF4 proteins in determining liverspecific and hormone-inducible TAT gene activity. Expression of HNF3a, -,B, and -y and HNF4 is activated early in liver cell differentiation and remains unchanged in the perinatal period (P. Monaghan and G.S., unpublished work). Since the TAT gene is switched on only shortly after birth, concomitant with changes in hormone concentrations, these findings also indicate a role of signal transduction pathways in the developmental activation of the gene. At birth, insulin concentrations decrease whereas glucagon/cAMP and glucocorticoid levels rise (40) . The increase in intracellular cAMP levels, a response to the neonatal hypoglycemia, affects the binding of and trans-activation by the CRE binding protein CREB (21, 41, 42) thereby counteracting the inhibitory effect of insulin on CRE function (R. Ganss, F. Weih, and G.S., unpublished work). We propose that the synergism between constitutive liver-specific control sequences and targets of hormonal signal transduction pathways determines the correct developmental activation of the TAT gene in the liver.
